Hepion Pharmaceuticals director Stetz buys $25,000 in common stock

Hepion Pharmaceuticals' director Gary S. Stetz II bolstered his stake in the company by acquiring an additional 500,000 shares of common stock on August 3, 2026. The purchase, made at the stock's present level of $0.05 per share, cost him $25,000. Despite the company's relatively small market cap of $4.5 million, InvestingPro analysis suggests the stock is overvalued, having dropped 15% in the previous week.

On the same day, Stetz expanded his portfolio further by purchasing 500,000 warrants for Hepion Pharmaceuticals common stock, with an exercise price of $0.06 and an expiration date of August 3, 2031. An InvestingPro tip warns investors of the stock's propensity for high price volatility. Hepion Pharmaceuticals also recently concluded its 2026 Annual Meeting of Stockholders, during which stockholders voted on three proposals.

The election of five new directors, including Stetz, was among the key outcomes. The vote counts for each nominee ranged from 13,186,912 to 13,503,469 in favor, with 149,233 to 465,790 votes withheld, and 4,816,704 broker non-votes.